Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

The New York-based pharma giant generated adjusted earnings of $0.60 a share on revenue of $13.28B that grew 2.2% ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with ...

But is the stock still worth buying in hopes of a recovery over the long term? To answer that question in more detail, let's put this setback into context.

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Pfizer Inc.’s stock rose 2.7% early Tuesday ... plan and raised its revenue and profit guidance for the year. New York-based Pfizer had net income of $41 million, or 1 cent a share, for the ...

NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...

NEW YORK - Pfizer Inc. (NYSE ... a high EBITDA valuation multiple, Pfizer's PEG Ratio for the last twelve months as of Q2 2024 is 0.58, suggesting that the stock may be undervalued based on ...

However, the Hold rating suggests that while Pfizer’s financial and operational strategies are solid, the potential for significant stock appreciation ... in New York, NY. Read More on PFE ...

Global investment management firm AllianceBernstein LP (NYSE: AB) has opened its new office at The Spiral, a 66-story office ...